查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1830813

2025年肺癌筛检全球市场报告

Lung Cancer Screening Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10个工作天内

价格
简介目录

近年来，肺癌筛检市场呈现强劲成长势头，市场规模从2024年的30.3亿美元增加至2025年的33.3亿美元，复合年增长率达9.9%。这段历史性时期的成长可归因于烟草使用率的上升、人们对早期癌症检测认识的提高、政府倡议和筛检计画的不断扩展、老年人口的增长以及私人诊断中心的普及率的提高。

预计未来几年肺癌筛检市场将强劲成长，到2029年将达到47.9亿美元，复合年增长率为9.5%。预测期内的成长动力来自诸多因素，例如日益加重的空气污染和职业暴露负担、支持早期筛检益处的新兴临床证据、保险覆盖范围的扩大、都市化进程加快和生活方式的改变，以及放射科基础设施投资的增加。这段时期的主要趋势包括：云端基础影像处理平台的整合、放射组学和影像分析的重大进展、可携式和照护现场影像处理设备的开发、决策支援系统与放射科工作流程的整合，以及基于非侵入性生物标记筛检的进展。

肺癌筛检是一种预防策略，旨在及早发现肺癌，通常在出现明显症状之前即可发现。它针对的是因某些健康和生活方式因素而处于高风险的人。该过程的目标是及早发现肺组织的异常变化或生长，从而增加有效治疗的机会，并降低疾病的整体影响。

肺癌筛检的主要诊断方法是低剂量螺旋CT和胸部X光检查。低剂量螺旋CT可以减少辐射，并产生详细的肺部截面影像，从而能够高灵敏度地早期发现肺部异常。这些检查适用于各种类型的肺癌，例如非小细胞肺癌和小细胞肺癌，以及不同年龄段，例如50岁以上和50岁以下。它们的终端用户众多，包括医院、诊所和诊断中心。

2025年春季美国突然提高关税以及由此引发的贸易摩擦严重影响了医疗保健产业，尤其是关键医疗设备、诊断设备和药品的供应。医院和医疗机构面临进口手术器械、影像设备以及注射器和导管等消耗品成本上涨的问题。这些成本上涨给医疗保健预算带来了巨大压力，导致一些医疗机构推迟设备升级或将成本转嫁给患者。此外，原料和零件的关税阻碍了基本药品和医疗设备的生产，造成了供应链瓶颈。为此，该行业正在筹资策略多样化，尽可能促进本地生产，并倡导紧急医疗产品免关税。

本研究报告是商业研究公司 (The Business Research Company) 新报告系列的一部分，该系列提供肺癌筛检市场统计数据，例如全球市场规模、区域份额、肺癌筛检市场份额的竞争对手、详细的肺癌筛检细分市场、市场趋势以及肺癌筛检行业的商机。本肺癌筛检市场研究报告对该行业的现状和未来趋势进行了详细分析，为您提供所需的一切观点。

吸烟率上升预计将推动肺癌筛检市场的成长。由于压力水平上升，吸烟（主要是吸入烟草燃烧产物产生的烟雾）的人数正在增加，越来越多的人将吸烟作为一种应对机制。肺癌筛检有助于应对这一趋势，因为它支持及早发现与吸烟相关的健康风险，促进戒烟，并支持减少烟草使用的公共卫生倡议。例如，根据国家统计局 2023 年 9 月的数据，2022 年英国约有 450 万成年人（占总人口的 8.7%）报告每天或偶尔使用电子烟，高于 2021 年的 7.7%。因此，吸烟率的上升正在推动肺癌筛检市场的发展。

肺癌筛检市场的主要企业正专注于人工智慧 (AI) 创新，以提高乳房摄影筛检影像的早期发现和诊断准确性。诸如正常标记之类的技术可提高诊断准确性，减少假阳性，并自动识别无异常观察的扫描结果，从而帮助确定病例的优先顺序以进行进一步审查。 2025 年 5 月，韩国医疗科技公司 Lunit Inc. 推出了 INSIGHT CXR4，这是一款由人工智慧驱动的下一代胸部 X 光分析解决方案。此系统可协助放射科医师检测 12 种胸部异常，包括肺结节、肺炎和急性骨折，并结合目前和历史影像比较等功能，用于早期疾病检测和临床决策支援。

2022年8月，美国医学影像软体供应商Intelerad 医疗图像 Systems Inc.收购了PenRad Technologies, Inc.，收购金额未揭露。透过此次收购，Intelerad旨在扩展其乳房X光摄影和肺癌筛检服务，提高放射科医生的工作流程效率，并改善患者预后。 PenRad Technologies Inc.专注于肺癌筛检软体，此次收购将增强Intelerad先进的影像解决方案能力。

肺癌筛检市场包括提供放射学解读、诊断追踪程序、患者风险评估和远距医疗咨询等服务的营业单位所获得的收益。市场价值还包括服务供应商销售或包含在服务产品中的相关商品的价值。仅包括营业单位之间交易或销售给最终消费者的商品和服务。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第四章 市场：宏观经济情景，包括利率、通膨、地缘政治、贸易战和关税，以及新冠疫情和復苏对市场的影响

第五章 全球成长分析与策略分析框架

  • 全球肺癌筛检：PESTEL分析（政治、社会、技术、环境、法律因素、驱动因素和限制因素）
  • 最终用途产业分析
  • 全球肺癌筛检市场：成长率分析
  • 全球肺癌筛检市场表现：规模与成长，2019-2024
  • 全球肺癌筛检市场预测：2024-2029年及2034年规模与成长
  • 全球肺癌筛检：总目标市场（TAM）

第六章 市场细分

  • 全球肺癌筛检市场按诊断类型、表现和预测，2019-2024 年、2024-2029 年、2034 年
  • 低剂量螺旋电脑断层扫描
  • 胸部X光检查
  • 全球肺癌筛检市场（按癌症类型、表现和预测），2019-2024 年、2024-2029 年、2034 年
  • 非小细胞肺癌（NSCLC）
  • 小细胞肺癌
  • 全球肺癌筛检市场：依年龄层划分，实际及预测，2019-2024 年、2024-2029 年、2034 年
  • 50岁或以上
  • 50岁以下
  • 全球肺癌筛检市场：按最终用户、实际结果和预测，2019-2024 年、2024-2029 年、2034 年
  • 医院和诊所
  • 诊断中心
  • 其他最终用户
  • 全球肺癌筛检市场：低剂量螺旋电脑断层扫描细分（按类型）、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 筛检
  • 诊断
  • 后续行动
  • 全球肺癌筛检市场：胸部X光相片细分（按类型）、绩效及预测，2019-2024年、2024-2029年、2034年
  • 后部 前部
  • 水平的
  • 可携式的

第七章 区域和国家分析

  • 全球肺癌筛检市场：按地区、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 全球肺癌筛检市场：依国家、绩效及预测（2019-2024 年、2024-2029 年及 2034 年）

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章：澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章 西欧市场

第十六章英国市场

第十七章：德国市场

第18章：法国市场

第十九章：义大利市场

第20章：西班牙市场

第21章 东欧市场

第22章俄罗斯市场

第23章 北美市场

第24章美国市场

第25章：加拿大市场

第26章 南美洲市场

第27章：巴西市场

第28章 中东市场

第29章：非洲市场

第30章：竞争格局与公司概况

  • 肺癌筛检市场：竞争格局
  • 肺癌筛检市场：公司简介
    • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
    • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
    • AstraZeneca Plc Overview, Products and Services, Strategy and Financial Analysis
    • Abbott Laboratories Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Canon Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章：其他领先和创新企业

  • Medtronic Plc
  • Siemens Healthineers AG
  • Koninklijke Philips NV
  • GE Healthcare Technologies Inc.
  • Quest Diagnostics Incorporated
  • Agilent Technologies Inc.
  • Shimadzu Corporation
  • NeoGenomics Laboratories Inc.
  • Freenome Holdings Inc.
  • Biodesix Inc.
  • Lunit Inc.
  • Infervision
  • Riverain Technologies
  • VisionGate
  • Delfi Diagnostics Inc.

第 32 章全球市场竞争基准化分析与仪表板

第33章 重大併购

第34章近期市场趋势

第 35 章：高潜力市场国家、细分市场与策略

  • 2029年肺癌筛检市场：提供新机会的国家
  • 2029年肺癌筛检市场：细分领域带来新机会
  • 2029年肺癌筛检市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手策略

第36章 附录

简介目录
Product Code: r37802

Lung cancer screening is a preventive strategy aimed at detecting cancer in the lungs at an early stage, often before any noticeable symptoms appear. It targets individuals at higher risk due to specific health or lifestyle factors. The goal of this process is to identify abnormal changes or growths in lung tissue early, improving the chances of effective treatment and reducing the overall impact of the disease.

The primary diagnostic methods for lung cancer screening include low-dose spiral computed tomography (CT) scans and chest X-rays. Low-dose spiral CT scans use reduced radiation to produce detailed cross-sectional images of the lungs, allowing early detection of lung abnormalities with high sensitivity. These scans are applied for different lung cancer types, including non-small cell lung cancer and small cell lung cancer, and across various age groups, such as individuals aged 50 and older or below 50. They are utilized by multiple end users, including hospitals, clinics, diagnostic centers, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The lung cancer screening market research report is one of a series of new reports from The Business Research Company that provides lung cancer screening market statistics, including the lung cancer screening industry global market size, regional shares, competitors with the lung cancer screening market share, detailed lung cancer screening market segments, market trends, and opportunities, and any further data you may need to thrive in the lung cancer screening industry. This lung cancer screening market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The lung cancer screening market size has grown strongly in recent years. It will grow from $3.03 billion in 2024 to $3.33 billion in 2025 at a compound annual growth rate (CAGR) of 9.9%. The growth during the historic period can be attributed to the rising prevalence of tobacco use, increasing awareness of early cancer detection, expansion of government initiatives and screening programs, a growing geriatric population, and greater penetration of private diagnostic centers.

The lung cancer screening market size is expected to see strong growth in the next few years. It will grow to $4.79 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%. The growth during the forecast period can be attributed to the increasing burden of air pollution and occupational exposures, rising clinical evidence supporting the benefits of early screening, expanding availability of insurance coverage, growing urbanization and lifestyle changes, and rising investments in radiology infrastructure. Key trends in this period include the integration of cloud-based imaging platforms, advancements in radiomics and image analytics, development of portable and point-of-care imaging devices, incorporation of decision support systems into radiology workflows, and progress in non-invasive biomarker-based screening.

The rising smoking rates are expected to drive growth in the lung cancer screening market. Smoking, the inhalation of smoke from burning substances, primarily tobacco has been increasing due to rising stress levels, with more individuals turning to smoking as a coping mechanism. Lung cancer screening helps address this trend by enabling early detection of smoking-related health risks, encouraging smoking cessation, and supporting public health initiatives to reduce tobacco use. For example, according to the Office for National Statistics in September 2023, around 4.5 million adults in Great Britain, or 8.7% of the population, reported using e-cigarettes either daily or occasionally in 2022, up from 7.7% in 2021. Therefore, the growing prevalence of smoking is fueling the lung cancer screening market.

Key players in the lung cancer screening market are focusing on innovations in artificial intelligence (AI) to improve early detection and diagnostic precision in chest imaging. Technologies such as normal flagging enhance diagnostic accuracy, reduce false positives, and help prioritize cases that require further review by automatically identifying scans with no abnormal findings. In May 2025, Lunit Inc., a South Korea-based medtech company, launched INSIGHT CXR4, its next-generation AI-powered chest X-ray analysis solution, now CE MDR-certified for use across Europe. This system assists radiologists by detecting 12 chest abnormalities including lung nodules, pneumonia, and acute bone fractures and incorporates features such as current-prior image comparison to support early disease detection and clinical decision-making.

In August 2022, Intelerad Medical Systems Inc., a U.S.-based medical imaging software provider, acquired PenRad Technologies, Inc. for an undisclosed sum. Through this acquisition, Intelerad aims to expand its offerings in mammography and lung cancer screening, improving workflow efficiency for radiologists and enhancing patient outcomes. PenRad Technologies Inc. specializes in lung cancer screening software, strengthening Intelerad's capabilities in advanced imaging solutions.

Major players in the lung cancer screening market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, AstraZeneca Plc, Abbott Laboratories Inc., Canon Inc., Medtronic Plc, Siemens Healthineers AG, Koninklijke Philips N.V., GE Healthcare Technologies Inc., Quest Diagnostics Incorporated, Agilent Technologies Inc., Shimadzu Corporation, NeoGenomics Laboratories Inc., Freenome Holdings Inc., Biodesix Inc., Lunit Inc., Infervision, Riverain Technologies, VisionGate, and Delfi Diagnostics Inc.

North America was the largest region in the lung cancer screening market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in lung cancer screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the lung cancer screening market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The lung cancer screening market includes revenues earned by entities by providing services such as radiology interpretation, diagnostic follow-up procedures, patient risk assessment, and telehealth consultation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Lung Cancer Screening Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on lung cancer screening market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for lung cancer screening ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The lung cancer screening market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Diagnosis Type: Low Dose Spiral Computed Tomography Scan; Chest-X-Ray
  • 2) By Cancer Type: Non-Small Cell Lung Cancer; Small Cell Lung Cancer
  • 3) By Age Group: 50 And Older; Below 50
  • 4) By End-User: Hospitals And Clinics; Diagnostic Centers; Other End-Users
  • Subsegments:
  • 1) By Low Dose Spiral Computed Tomography Scan: Screening; Diagnostic; Follow-Up
  • 2) By Chest X-Ray: Posterior Anterior; Lateral; Portable
  • Companies Mentioned: Johnson & Johnson Services Inc.; F. Hoffmann-La Roche AG; AstraZeneca Plc; Abbott Laboratories Inc.; Canon Inc.; Medtronic Plc; Siemens Healthineers AG; Koninklijke Philips N.V.; GE Healthcare Technologies Inc.; Quest Diagnostics Incorporated; Agilent Technologies Inc.; Shimadzu Corporation; NeoGenomics Laboratories Inc.; Freenome Holdings Inc.; Biodesix Inc.; Lunit Inc.; Infervision; Riverain Technologies; VisionGate; Delfi Diagnostics Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Lung Cancer Screening Market Characteristics

3. Lung Cancer Screening Market Trends And Strategies

4. Lung Cancer Screening Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Lung Cancer Screening Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Lung Cancer Screening PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Lung Cancer Screening Market Growth Rate Analysis
  • 5.4. Global Lung Cancer Screening Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Lung Cancer Screening Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Lung Cancer Screening Total Addressable Market (TAM)

6. Lung Cancer Screening Market Segmentation

  • 6.1. Global Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Low Dose Spiral Computed Tomography Scan
  • Chest-X-Ray
  • 6.2. Global Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Non-Small Cell Lung Cancer (NSCLC)
  • Small Cell Lung Cancer
  • 6.3. Global Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 50 And Older
  • Below 50
  • 6.4. Global Lung Cancer Screening Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals And Clinics
  • Diagnostic Centers
  • Other End-Users
  • 6.5. Global Lung Cancer Screening Market, Sub-Segmentation Of Low Dose Spiral Computed Tomography Scan, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Screening
  • Diagnostic
  • Follow-Up
  • 6.6. Global Lung Cancer Screening Market, Sub-Segmentation Of Chest X-Ray, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Posterior Anterior
  • Lateral
  • Portable

7. Lung Cancer Screening Market Regional And Country Analysis

  • 7.1. Global Lung Cancer Screening Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Lung Cancer Screening Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Lung Cancer Screening Market

  • 8.1. Asia-Pacific Lung Cancer Screening Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Lung Cancer Screening Market

  • 9.1. China Lung Cancer Screening Market Overview
  • 9.2. China Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Lung Cancer Screening Market

  • 10.1. India Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Lung Cancer Screening Market

  • 11.1. Japan Lung Cancer Screening Market Overview
  • 11.2. Japan Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Lung Cancer Screening Market

  • 12.1. Australia Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Lung Cancer Screening Market

  • 13.1. Indonesia Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Lung Cancer Screening Market

  • 14.1. South Korea Lung Cancer Screening Market Overview
  • 14.2. South Korea Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Lung Cancer Screening Market

  • 15.1. Western Europe Lung Cancer Screening Market Overview
  • 15.2. Western Europe Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Lung Cancer Screening Market

  • 16.1. UK Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Lung Cancer Screening Market

  • 17.1. Germany Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Lung Cancer Screening Market

  • 18.1. France Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Lung Cancer Screening Market

  • 19.1. Italy Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Lung Cancer Screening Market

  • 20.1. Spain Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Lung Cancer Screening Market

  • 21.1. Eastern Europe Lung Cancer Screening Market Overview
  • 21.2. Eastern Europe Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Lung Cancer Screening Market

  • 22.1. Russia Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Lung Cancer Screening Market

  • 23.1. North America Lung Cancer Screening Market Overview
  • 23.2. North America Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Lung Cancer Screening Market

  • 24.1. USA Lung Cancer Screening Market Overview
  • 24.2. USA Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Lung Cancer Screening Market

  • 25.1. Canada Lung Cancer Screening Market Overview
  • 25.2. Canada Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Lung Cancer Screening Market

  • 26.1. South America Lung Cancer Screening Market Overview
  • 26.2. South America Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Lung Cancer Screening Market

  • 27.1. Brazil Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Lung Cancer Screening Market

  • 28.1. Middle East Lung Cancer Screening Market Overview
  • 28.2. Middle East Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Lung Cancer Screening Market

  • 29.1. Africa Lung Cancer Screening Market Overview
  • 29.2. Africa Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Lung Cancer Screening Market Competitive Landscape And Company Profiles

  • 30.1. Lung Cancer Screening Market Competitive Landscape
  • 30.2. Lung Cancer Screening Market Company Profiles
    • 30.2.1. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. AstraZeneca Plc Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Abbott Laboratories Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Canon Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Lung Cancer Screening Market Other Major And Innovative Companies

  • 31.1. Medtronic Plc
  • 31.2. Siemens Healthineers AG
  • 31.3. Koninklijke Philips N.V.
  • 31.4. GE Healthcare Technologies Inc.
  • 31.5. Quest Diagnostics Incorporated
  • 31.6. Agilent Technologies Inc.
  • 31.7. Shimadzu Corporation
  • 31.8. NeoGenomics Laboratories Inc.
  • 31.9. Freenome Holdings Inc.
  • 31.10. Biodesix Inc.
  • 31.11. Lunit Inc.
  • 31.12. Infervision
  • 31.13. Riverain Technologies
  • 31.14. VisionGate
  • 31.15. Delfi Diagnostics Inc.

32. Global Lung Cancer Screening Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Lung Cancer Screening Market

34. Recent Developments In The Lung Cancer Screening Market

35. Lung Cancer Screening Market High Potential Countries, Segments and Strategies

  • 35.1 Lung Cancer Screening Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Lung Cancer Screening Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Lung Cancer Screening Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer